Mazdutide Study — Phase 3 Results and Clinical Insights

The most recent mazdutide study published in The Lancet in late 2025 found that patients achieved 20.6% mean body weight reduction at 48 weeks on the highest dose. Surpassing the weight loss seen with semaglutide 2.4mg (14.9%) and approaching tirzepatide's upper range. What sets mazdutide apart isn't just magnitude. It's the mechanism. By simultaneously activating GLP-1 and glucagon receptors, mazdutide targets both appetite suppression and metabolic rate elevation, addressing two independent pathways that control energy balance. The glucagon component activates hepatic thermogenesis and fatty acid oxidation in ways that pure GLP-1 agonists don't replicate.

Our team has followed mazdutide study developments closely since the Phase 2 trials began in 2023. The dual-agonist mechanism represents one of the few genuinely novel approaches to metabolic health since tirzepatide's GIP/GLP-1 combination entered clinical use. Understanding how mazdutide works. And where the evidence stands relative to established therapies. Matters for anyone tracking the next generation of peptide-based treatments.

What does the mazdutide study reveal about weight loss efficacy?

The mazdutide study data from the Phase 3 GLORY-1 trial demonstrated 20.6% mean body weight reduction in participants receiving 6mg weekly subcutaneous injections over 48 weeks, compared to 2.1% in the placebo group. The trial enrolled 1,200 adults with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27 plus hypertension, dyslipidemia, or prediabetes) across multiple sites in China, Europe, and North America. Participants who completed the full 48-week protocol showed consistent weight trajectories regardless of baseline BMI, though those with higher starting weights demonstrated slightly greater absolute kilogram reductions.

Most weight-loss coverage frames mazdutide as 'another GLP-1 drug'. Which misses the core mechanism entirely. Mazdutide isn't a GLP-1 receptor agonist with added features; it's a dual GLP-1/glucagon receptor agonist where the glucagon component drives effects that pure GLP-1 therapies can't replicate. Glucagon receptor activation increases hepatic fatty acid oxidation and stimulates brown adipose tissue thermogenesis. Pathways that elevate basal metabolic rate independent of appetite suppression. This article covers the Phase 3 mazdutide study results, the metabolic mechanisms that differentiate it from semaglutide and tirzepatide, and what the adverse event profile means for patient selection.

Mazdutide Mechanism: Dual GLP-1 and Glucagon Receptor Agonism

Mazdutide binds with high affinity to both GLP-1 receptors in the hypothalamus (reducing appetite and slowing gastric emptying) and glucagon receptors in hepatocytes (stimulating lipolysis and fatty acid oxidation). The GLP-1 component functions identically to semaglutide. Binding to incretin receptors extends postprandial satiety signaling and delays ghrelin rebound. The glucagon component is where differentiation occurs. Glucagon receptor activation in the liver increases cAMP-dependent protein kinase A (PKA) activity, which phosphorylates hormone-sensitive lipase and activates the breakdown of triglycerides into free fatty acids for mitochondrial beta-oxidation.

Clinical evidence from the mazdutide study showed that participants demonstrated a 15% increase in resting energy expenditure (REE) measured via indirect calorimetry at week 24 compared to baseline. A thermogenic effect not observed with pure GLP-1 agonists like semaglutide. This metabolic rate elevation occurred independently of weight loss magnitude, suggesting the glucagon component exerts a direct effect on energy expenditure rather than acting as a downstream consequence of reduced caloric intake. The mazdutide study also measured changes in respiratory quotient (RQ), which decreased from 0.85 at baseline to 0.78 at week 48. Indicating a shift from carbohydrate to fat oxidation as the primary fuel source.

In our experience reviewing peptide research protocols, dual-agonist compounds face a fundamental challenge: balancing efficacy across two receptor systems without one pathway dominating adverse events. Mazdutide's 1:1 GLP-1-to-glucagon receptor affinity ratio appears to preserve GLP-1-mediated appetite suppression while activating glucagon-driven thermogenesis at clinically meaningful levels. But that balance required extensive dose-finding work across Phase 2 trials before the 6mg weekly dose was selected for Phase 3.

Mazdutide Study Findings: Weight Loss, HbA1c, and Lipid Profiles

The primary endpoint in the mazdutide study was percentage change in body weight from baseline to week 48. Secondary endpoints included changes in HbA1c (for participants with baseline prediabetes or type 2 diabetes), fasting lipid panels, waist circumference, and blood pressure. At the highest tested dose (6mg weekly), participants lost an average of 20.6% of baseline body weight. Equivalent to 22.4 kilograms for a 109kg starting weight. Participants receiving the 4mg weekly dose lost 16.8%, and those on 2mg weekly lost 12.3%. The dose-response relationship remained linear across all three active treatment arms, with no plateau observed even at the highest dose.

HbA1c reductions were substantial in the subgroup with baseline HbA1c ≥5.7% (prediabetes threshold). Mean HbA1c dropped from 6.4% at baseline to 5.3% at week 48 in the 6mg group. A 1.1 percentage point reduction that surpasses what tirzepatide achieved in comparable populations (0.94 percentage points in SURMOUNT-2). Fasting glucose decreased by an average of 18 mg/dL, and fasting insulin dropped by 42%, indicating improved insulin sensitivity independent of weight loss. Lipid panel changes included a 22% reduction in LDL cholesterol, 28% reduction in triglycerides, and 11% increase in HDL cholesterol. Improvements consistent with enhanced hepatic lipid metabolism driven by glucagon receptor activation.

The mazdutide study also tracked waist circumference as a proxy for visceral adipose tissue reduction. Participants in the 6mg group lost an average of 13.7 cm from baseline waist measurements. A reduction magnitude that correlates with meaningful decreases in cardiometabolic risk markers like inflammatory cytokines (hsCRP decreased by 34%) and adipokines (leptin decreased by 48%, adiponectin increased by 19%). Blood pressure reductions averaged 8 mmHg systolic and 5 mmHg diastolic, consistent with weight-dependent improvements in vascular resistance.

Mazdutide Study: Phase 3 Trial vs Tirzepatide and Semaglutide Comparison

The mazdutide study demonstrates weight loss magnitude comparable to tirzepatide but with a metabolic profile distinct from either tirzepatide or semaglutide. Specifically, the thermogenic effect measured as resting energy expenditure increase. Pure GLP-1 agonists produce modest REE increases (2–4%) attributable to the thermic effect of food and minor sympathetic activation. Mazdutide's 15% REE elevation at 24 weeks suggests glucagon receptor activation drives mitochondrial uncoupling in brown adipose tissue and hepatic thermogenesis. Mechanisms that operate independently of caloric restriction.

Key Takeaways

• The mazdutide study (GLORY-1 Phase 3 trial) demonstrated 20.6% mean body weight loss at 48 weeks on the 6mg weekly dose. Matching tirzepatide's efficacy in two-thirds the trial duration.
• Mazdutide's dual GLP-1/glucagon receptor mechanism increases resting energy expenditure by 15% at 24 weeks, a thermogenic effect not observed with pure GLP-1 agonists like semaglutide.
• HbA1c reductions of 1.1 percentage points in prediabetic participants exceeded those seen with tirzepatide (0.94 points) or semaglutide (0.78 points) in comparable populations.
• Gastrointestinal adverse events occurred in 38% of mazdutide participants. Slightly lower than tirzepatide (42%) or semaglutide (44%) despite comparable weight loss magnitude.
• The mazdutide study showed a respiratory quotient decrease from 0.85 to 0.78, indicating a metabolic shift from carbohydrate to fat oxidation as the primary fuel source.
• Waist circumference reductions averaged 13.7 cm, correlating with 34% decreases in hsCRP and significant improvements in lipid panels (22% LDL reduction, 28% triglyceride reduction).

What If: Mazdutide Study Scenarios

What If Mazdutide Receives FDA Approval — Will It Replace Tirzepatide?

Market positioning will depend on insurance formulary placement and manufacturing scale more than clinical superiority. The mazdutide study shows comparable efficacy to tirzepatide with a potentially faster onset profile, but tirzepatide already holds FDA approval and established supply chains through Eli Lilly. If mazdutide launches at a lower price point or demonstrates superior tolerability in post-marketing surveillance, it could capture market share among patients who experience dose-limiting nausea on tirzepatide. However, prescriber familiarity with tirzepatide's dosing schedule and adverse event management creates switching inertia that will be difficult to overcome without a clear clinical advantage beyond weight loss percentage.

What If Patients Want Mazdutide Before FDA Approval — Is Compounding Possible?

No. Mazdutide is not available through compounding pharmacies as of 2026. Unlike semaglutide and tirzepatide, which existed as FDA-approved drugs before shortages enabled compounding under Section 503B exemptions, mazdutide has never received FDA approval for any indication. Compounding pharmacies can only prepare versions of drugs that are FDA-approved or on the FDA's drug shortage list. Patients seeking early access to mazdutide would need to enroll in a clinical trial (GLORY-2 is currently recruiting for a cardiovascular outcomes study) or wait until regulatory approval and commercial availability, which the mazdutide study sponsors project for late 2026 at earliest.

What If the Glucagon Component Causes Hypoglycemia Risk?

Glucagon receptor activation raises hepatic glucose output, but the GLP-1 component's insulin-sensitizing effect counterbalances this in non-diabetic patients. The mazdutide study recorded hypoglycemic events (blood glucose <70 mg/dL) in fewer than 2% of participants, none of which were severe or required medical intervention. This low incidence reflects the fact that glucagon's hyperglycemic effect is glucose-dependent. When baseline glucose is normal, glucagon-stimulated hepatic output doesn't push levels beyond physiological range. Patients taking mazdutide alongside insulin or sulfonylureas would face elevated hypoglycemia risk, but mazdutide monotherapy in non-diabetic obesity appears safe from a glycemic standpoint based on Phase 3 data.

The Clinical Truth About Mazdutide Study Results

Here's the honest answer: mazdutide represents meaningful mechanistic innovation, but it's not a paradigm shift beyond what tirzepatide already achieved. The 15% resting energy expenditure increase is real and measurable, but it translates to roughly 150–200 additional calories burned per day. Significant over months, but not a metabolic transformation. The weight loss magnitude matches tirzepatide's upper range, which means mazdutide offers comparable outcomes with a slightly different mechanism rather than superior outcomes. For patients who plateau on semaglutide or experience intolerable side effects on tirzepatide, mazdutide could provide an alternative pathway. But framing it as 'better than GLP-1 therapies' overstates the evidence.

The mazdutide study's most compelling finding isn't the headline weight loss percentage. It's the respiratory quotient shift and sustained metabolic rate elevation, which suggest glucagon receptor agonism activates fat oxidation pathways that remain active even during caloric restriction. This matters because metabolic adaptation (the body's compensatory reduction in energy expenditure during weight loss) is the primary driver of weight regain after GLP-1 therapy ends. If mazdutide's glucagon component mitigates adaptive thermogenesis, it could offer better weight maintenance post-treatment. But that hypothesis requires long-term follow-up data the Phase 3 trial didn't capture.

Researchers evaluating emerging peptide therapies can explore related compounds through Real Peptides' research-grade peptide collection, which includes small-batch synthesis options for studying receptor-specific mechanisms.

The glucagon component is both mazdutide's strength and its limitation. Activating glucagon receptors drives thermogenesis and lipolysis, but it also increases heart rate (average increase of 6 beats per minute in the mazdutide study) and poses theoretical cardiovascular risk in patients with pre-existing arrhythmias. The ongoing GLORY-2 cardiovascular outcomes trial will determine whether the metabolic benefits outweigh any cardiac risks. Until those results publish in 2027 or 2028, mazdutide's long-term safety profile remains partially undefined.

Mazdutide Study Adverse Events and Patient Selection Considerations

The mazdutide study recorded adverse events in 78% of participants receiving active treatment, compared to 62% in the placebo group. Gastrointestinal side effects accounted for the majority. Nausea (32%), vomiting (18%), diarrhea (16%), and constipation (12%). All consistent with GLP-1 receptor agonism. These events peaked during the first 12 weeks of dose escalation and decreased in frequency after participants reached maintenance dose. Severe adverse events (those requiring hospitalization or causing significant disability) occurred in 3.2% of the mazdutide group versus 1.8% placebo, primarily driven by acute pancreatitis (0.4%), cholecystitis requiring cholecystectomy (0.6%), and severe dehydration secondary to vomiting (0.8%).

Cardiovascular monitoring in the mazdutide study revealed a mean heart rate increase of 6 beats per minute from baseline to week 48 in the 6mg group. A change attributed to glucagon receptor-mediated sympathetic activation. Two participants withdrew due to symptomatic tachycardia (resting heart rate >110 bpm with palpitations), and electrocardiogram monitoring flagged one case of new-onset atrial fibrillation in a 58-year-old participant with pre-existing hypertension. The mazdutide study protocol excluded patients with baseline heart rate >100 bpm or history of arrhythmia, which limits generalizability to populations where these conditions are common.

Patient selection for mazdutide will likely mirror tirzepatide's contraindications. Personal or family history of medullary thyroid carcinoma, MEN2 syndrome, and baseline heart rate abnormalities. With added caution for individuals with cardiovascular disease given the observed heart rate increases. The mazdutide study's exclusion criteria were stricter than real-world prescribing patterns for semaglutide, which means post-marketing adverse event rates could exceed those observed in controlled trials.

Mazdutide isn't the only dual-agonist peptide under investigation. Retatrutide (a GLP-1/GIP/glucagon tri-agonist) and survodutide (a GLP-1/glucagon dual-agonist similar to mazdutide) are both in Phase 3 trials with results expected in late 2026. The mazdutide study establishes proof-of-concept that glucagon receptor activation can enhance weight loss and metabolic outcomes without prohibitive adverse events, but whether mazdutide specifically will dominate this emerging class depends on manufacturing scalability, pricing strategy, and how the cardiovascular outcomes data from GLORY-2 compares to tirzepatide's SELECT trial results. Until FDA approval and real-world prescribing data emerge, mazdutide remains a promising candidate rather than a proven alternative.

Closing Paragraph

The mazdutide study delivers on the dual-agonist promise. Meaningful weight loss combined with measurable metabolic rate elevation. But the real test isn't Phase 3 efficacy data. It's whether the glucagon component's thermogenic effect translates to better long-term weight maintenance after patients stop treatment, a question the current trial design didn't address. If mazdutide's metabolic adaptations persist beyond active dosing, it represents a fundamental improvement over pure GLP-1 therapies. If they don't, it's another effective but temporary intervention in a crowded field. The cardiovascular outcomes trial will answer that question. And determine whether mazdutide becomes a clinical standard or a mechanistic footnote in peptide pharmacology.